Media, investors, advocacy organizations and others, please contact us here.

Publications

Access Travere’s peer-reviewed publications.

Home » Publications
Year
Therapeutic Area
Product

Results 35

Sort by

Publications FSGS

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

View
Publications IgAN

Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease

View
Publications IgAN

Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgA immune complexes in a mouse model of IgA nephropathy

View
Publications IgAN

Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

View
Publications IgAN

Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile

View
Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications FSGS

Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Publications

Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential

View
Publications IgAN

Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Publications IgAN

Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database

View
Publications IgAN

Sparsentan is superior to losartan in the gddY mouse model 1 of IgA nephropathy

View
Publications IgAN

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

View